Drug-induced heart failure

Maxwell, Carleton B.; Jenkins, Antoine T.
October 2011
American Journal of Health-System Pharmacy;10/1/2011, Vol. 68 Issue 19, p1791
Academic Journal
Purpose. The published evidence on the role of various drugs and medication classes in causing or exacerbating heart failure (HF) is reviewed, with discussion of precautions and management strategies for use in clinical practice. Summary. A literature search was conducted to identify reports of new-onset HF and exacerbations of HF associated with medication use published from 1960 to January 2011. A large body of evidence from controlled clinical trials has led to an improved understanding of well-established causes of drug-induced HF symptoms (e.g., thiazolidinediones, certain older chemotherapy agents) while implicating a wide range of other commonly used drugs and drug classes (e.g., tyrosine kinase inhibitors, biological response modifiers) as having causal or contributory roles. Among the various medications cited in cases of drug-induced HF, some have been linked to significantly increased risks of stroke, myocardial infarction, and death, particularly in patients with existing cardiovascular (CV) disorders or CV risk factors. In recent years, postmarketing and surveillance data have linked a number of newer medications--including the antiarrhythmic dronedarone, the antifungal itraconazole, and the anti-cancer drugs trastuzumab, lapatinib, and bevacizumab--to serious cardiac effects not reported during clinical trials. Conclusion. A variety of agents have been associated with drug-induced HF. Patients receiving agents that have been implicated in cases of new-onset HF or exacerbations of HF should be monitored for signs and symptoms of CV effects.


Related Articles

  • Mechanisms underlying endothelium-dependent, nitric oxide- and prostanoid-independent relaxation in monkey and dog coronary arteries. Fujioka, Hideyuki; Ayajiki, Kazuhide; Shinozaki, Kazuya; Toda, Noboru; Okamura, Tomio // Naunyn-Schmiedeberg's Archives of Pharmacology;Nov2002, Vol. 366 Issue 5, p488 

    We compared the mechanisms of vasorelaxation of acetylcholine and of substance P with reference to K+ channels, and analyzed pharmacologically the nature of endothelium-derived substance(s) other than NO and prostanoids in monkey and dog coronary arteries. Coronary arteries were isolated from...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;3/15/2012, Vol. 69 Issue 6, p446 

    The article reports some of the new drugs and dosage forms including Balsalazide disodium tablets for active ulcerative colitis in men, Ivermectin lotion for topical treatment of head lice infestations, and Mitomycin for ophthalmic solution as an adjunct to glaucoma filtration surgery.

  • Cardiac effects of non-cardiac drugs. Hopper, Ingrid // Australian Prescriber;Apr2011, Vol. 34 Issue 2, p52 

    Drugs prescribed for non-cardiac conditions can have unexpected and serious cardiac effects. These may occur while taking the drug or can be delayed for years. Often these adverse effects are not recognised until the postmarketing phase of drug development. An underlying cardiac abnormality can...

  • Leflunomide for the successful management of juvenile Cogan's syndrome. Liyi Xie; Yubo Cai; Xuhui Bao; Lanfang Cao // Clinical Rheumatology;Dec2009, Vol. 28 Issue 12, p1453 

    Cogan's syndrome (CS) is a rare multisystemic disorder characterized by inflammatory eye diseases and vestibuloauditory dysfunctions. It is prone to be misdiagnosed or overlooked, and the prognosis of those delayed-diagnosed CS is not optimistic. Despite isolated patient responses to systemic...

  • Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes. SHIH-WEI CHEN; YU-TSE TSAN; JONG-DAR CHEN; HUI-I HSIEH; CHANG-HSING LEE; HSIEN-HO LIN; JUNG-DER WANG; PAU-CHUNG CHEN // Diabetes Care;Feb2013, Vol. 36 Issue 2, p369 

    OBJECTIVE--Preclinical data suggest that peroxisome proliferator--activated receptor γ (PPARγ) agonists have anti neoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARg agonists, represented by thiazolidinediones (TZDs), and the risk...

  • Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm. DeJongh, Beth; Birkeland, Kade; Brenner, Michael // American Journal of Cardiovascular Drugs;Jun2015, Vol. 15 Issue 3, p171 

    Heart failure (HF) affects approximately 5.1 million adults in the USA, with expectations of a rise to nearly 8 million adults by 2030. Patients with HF are at increased risk for morbidity/mortality, and comorbidities can further complicate care for these patients. Diabetes mellitus, chronic...

  • Cardiovascular events and COX-2 inhibitors. Haldey, E J; Pappagallo, M // JAMA: Journal of the American Medical Association;12/12/2001, Vol. 286 Issue 22, p2809 

    No abstract available.

  • Herceptin use gains draft NICE approval.  // GP: General Practitioner;6/16/2006, p10 

    The article reports that Herceptin should be given to all eligible women on the NHS, according to a draft NICE technology appraisal issued last week. A one-year course of Herceptin is recommended after surgery, chemotherapy and radiotherapy among women with HER2-positive tumours, who represent a...

  • Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft. Zhang, Anli; Guodong Shen; Ting Zhao; Guihong Zhang; Jing Liu; Lihua Song; Wei Wei; Ling Bing; Zhengsheng Wu; Qiang Wu // Journal of Ovarian Research;2010, Vol. 3 Issue 1, p1 

    Background: chA21 is a novel tumor-inhibitory antibody which recognized subdomain I of HER2 extracellular domain with an epitope distinct from other HER2 antibodies. Previously, we demonstrated that chA21 inhibits human ovarian carcinoma cell line SKOV-3 growth in vitro and in vivo study. In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics